{"product_id":"protein-homeostasis-in-drug-discovery-isbn-9781119774129","title":"Protein Homeostasis in Drug Discovery","description":"\u003cb\u003eProtein Homeostasis in Drug Discovery\u003c\/b\u003e \u003cp\u003e\u003cb\u003eComprehensive resource on all aspects of protein homeostasis, covering both historical perspectives and emerging technologies that are revolutionizing the field\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e highlights drug discovery and development efforts targeting protein homeostasis and considers the emerging appreciation that a protein’s activity may not be the only factor to consider when developing therapeutic agents.  \u003c\/p\u003e\u003cp\u003eThe chapters cover various aspects of protein homeostasis such as cellular localization, abundance, interactions, and more. Moreover, the text contains up-to-date information regarding targeted protein degradation, an emerging drug discovery modality.  \u003c\/p\u003e\u003cp\u003eReaders interested in targeting different regulatory events that control protein homeostasis or modulating protein abundance will find this book an excellent resource. Furthermore, those interested in the link between biological function and regulating protein levels in living organisms, especially in the context of drug discovery, will learn from numerous examples discussed in this book. \u003c\/p\u003e\u003cp\u003eIn \u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e, readers can expect to find information on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eProtein folding, quality control, pharmacology, and drug targeting processes\u003c\/li\u003e \u003cli\u003e Recent advances in our understanding of protein homeostasis, covering emerging technologies and opportunities for therapeutic intervention \u003c\/li\u003e \u003cli\u003e Targeted protein degradation (TPD) and strategies such as PROTACs and molecular glues, including a chapter on TPD as an antiviral drug discovery strategy\u003c\/li\u003e \u003cli\u003e Drug discovery and development efforts aimed at correcting, stabilizing, and rescuing proteins, with examples included\u003c\/li\u003e \u003cli\u003e Advantages and key shortcomings of both phenotypic and target-based traditional drug discovery methods\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eCollectively, \u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e offers the reader an opportunity to learn more about the importance of considering and targeting protein homeostasis. The text is a must-read resource for academics, professionals in the pharmaceutical industry, and advanced students in various science-related fields. \u003c\/p\u003e\u003cp\u003eList of Contributors ix\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I Protein Folding and Quality Control in Drug Discovery 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Epichaperomes as a Gateway to Understanding, Diagnosing, and Treating Disease Through Rebalancing Protein–Protein Interaction Networks 3\u003cbr\u003e\u003ci\u003eChander S. Digwal, Sahil Sharma, Anand R. Santhaseela, Stephen D. Ginsberg, and Gabriela Chiosis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Stability of Steroid Hormone Receptors: The Intersection of Proteostasis and Selective Degradation 27\u003cbr\u003e\u003ci\u003eZachary J. Gale-Day and Jason E. Gestwicki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Pharmacological Chaperones: Therapeutic Potential for Diseases Resulting from GPCR Misfolding 65\u003cbr\u003e\u003ci\u003eSuli-Anne Laurin, Sajjad Ahrari, and Michel Bouvier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II Protein Degradation and Clearance as Drug Targeting Opportunities 135\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4 Exploiting the Proteasome for Disease Treatment: From Dynamic Architecture to Vast Functions 137\u003cbr\u003e\u003ci\u003eGwen R. Buel, Xiuxiu Lu, and Kylie J. Walters\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Targeting the Ubiquitination Cascade for Drug Discovery 179\u003cbr\u003e\u003ci\u003eQi Liu, Gabriel LaPlante, and Wei Zhang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Understanding, Targeting, and Hijacking Autophagy 227\u003cbr\u003e\u003ci\u003eHongguang Xia, Xiaoyan Xu, Mengxin Zhou, Manke Zhang, and Lingzhi Ye\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Deubiquitinating Enzymes: From Undruggable Targets to Emerging Opportunities 249\u003cbr\u003e\u003ci\u003eXiaoxi Liu, Laura Doherty, Alejandra Felix, and Sara Buhrlage\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III Redirecting Protein Degradation Processes for Drug Development 283\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8 History of IMiDs and Protein Degradation as a Pharmacological Modality 285\u003cbr\u003e\u003ci\u003eJunichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yuki Yamaguchi, and Hiroshi Handa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 PROTAC Degraders: Mechanism, Recent Advances, and Future Challenges 317\u003cbr\u003e\u003ci\u003eAlessio Ciulli and Oliver Hsia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Biochemical Principles of Targeted Protein Degradation 357\u003cbr\u003e\u003ci\u003eRoman V. Agafonov, Richard W. Deibler, William A. Elam, Joe S. Patel, and Stewart L. Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Pharmacology of PROTAC Degrader Molecules: Optimizing for In Vivo Performance 385\u003cbr\u003e\u003ci\u003eAndy Pike, Sofia Guzzetti, Pablo M. Morentin Gutierrez, and James S. Scott\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV Emerging Technologies and Future Opportunities 419\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Proximity-Inducing Bifunctional Molecules Beyond PROTACs 421\u003cbr\u003e\u003ci\u003eSophia Lai, Ashley E. Modell, and Amit Choudhary\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Strategies for Tag-Based Protein Control 447\u003cbr\u003e\u003ci\u003eBehnam Nabet, Nathanael S. Gray, and Fleur M. Ferguson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Targeted Protein Degradation in Antiviral Drug Discovery 465\u003cbr\u003e\u003ci\u003eMélissanne de Wispelaere and Priscilla L. Yang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Beyond Inhibition: Ligand-Based Pharmacological Exploration as a Strategy Toward New Targets and Modalities 491\u003cbr\u003e\u003ci\u003eMilka Kostic and Lyn H. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 519 \u003c\/p\u003e  \u003cp\u003e\u003cb\u003eMilka Kostic, PhD,\u003c\/b\u003e is the Program Director for Chemical Biology at the Dana-Farber Cancer Institute and her interests include advocating for the importance of chemical biology as a critical link in the chemistry-biology-medicine continuum. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eLyn H. Jones, PhD,\u003c\/b\u003e is currently Director of the Center for Protein Degradation at the Dana-Farber Cancer Institute and his interests include using chemogenomics and chemoproteomics to advance new therapeutic modalities.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eComprehensive resource on all aspects of protein homeostasis, covering both historical perspectives and emerging technologies that are revolutionizing the field\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e highlights drug discovery and development efforts targeting protein homeostasis and considers the emerging appreciation that a protein’s activity may not be the only factor to consider when developing therapeutic agents.  \u003c\/p\u003e\u003cp\u003eThe chapters cover various aspects of protein homeostasis such as cellular localization, abundance, interactions, and more. Moreover, the text contains up-to-date information regarding targeted protein degradation, an emerging drug discovery modality.  \u003c\/p\u003e\u003cp\u003eReaders interested in targeting different regulatory events that control protein homeostasis or modulating protein abundance will find this book an excellent resource. Furthermore, those interested in the link between biological function and regulating protein levels in living organisms, especially in the context of drug discovery, will learn from numerous examples discussed in this book. \u003c\/p\u003e\u003cp\u003eIn \u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e, readers can expect to find information on: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eProtein folding, quality control, pharmacology, and drug targeting processes\u003c\/li\u003e \u003cli\u003e Recent advances in our understanding of protein homeostasis, covering emerging technologies and opportunities for therapeutic intervention \u003c\/li\u003e \u003cli\u003e Targeted protein degradation (TPD) and strategies such as PROTACs and molecular glues, including a chapter on TPD as an antiviral drug discovery strategy\u003c\/li\u003e \u003cli\u003e Drug discovery and development efforts aimed at correcting, stabilizing, and rescuing proteins, with examples included\u003c\/li\u003e \u003cli\u003e Advantages and key shortcomings of both phenotypic and target-based traditional drug discovery methods\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eCollectively, \u003ci\u003eProtein Homeostasis in Drug Discovery\u003c\/i\u003e offers the reader an opportunity to learn more about the importance of considering and targeting protein homeostasis. The text is a must-read resource for academics, professionals in the pharmaceutical industry, and advanced students in various science-related fields.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989880094949,"sku":"NP9781119774129","price":225.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119774129.jpg?v=1761785771","url":"https:\/\/k12savings.com\/products\/protein-homeostasis-in-drug-discovery-isbn-9781119774129","provider":"K12savings","version":"1.0","type":"link"}